ClinicalTrialsFinder
RecruitingNot ApplicableNCT05724875

FLASH Radiotherapy for Skin Cancer

Randomized Phase II Selection Trial of FLASH Versus Conventional Radiotherapy for Patients with Localized Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

Sponsor

Centre Hospitalier Universitaire Vaudois

Enrollment

60 participants

Start Date

Jun 22, 2023

Study Type

INTERVENTIONAL

Conditions

Cutaneous Squamous Cell CarcinomaBasal Cell Carcinoma

Summary

This is a single center randomized selected Phase II study of FLASH radiotherapy (RT) versus standard of care (SOC) radiotherapy in patients with localized Cutaneous Squamous Cell Carcinoma (cSCC) or Basal Cell Carcinoma (BCC). In summary, the aims of the study are to describe and compare the toxicity and efficacy of high dose rate radiotherapy (FLASH therapy) to SOC conventional radiotherapy (according to the standard guidelines per lesion size) through a randomized Phase II selection study in patients presenting localized cSCC or BCC requiring a radiotherapy treatment.

Eligibility

Min Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new type of radiation called FLASH radiotherapy for skin cancer. FLASH delivers radiation much faster than standard treatment, which may reduce damage to surrounding healthy tissue while still effectively treating the cancer. **You may be eligible if...** - You are 60 years old or older - You have been diagnosed with a type of skin cancer called squamous cell carcinoma (cSCC) or basal cell carcinoma (BCC), confirmed by biopsy or special imaging - Your general health is reasonably good (Karnofsky score of 60 or higher) **You may NOT be eligible if...** - Your tumor is too large or deeply invasive for this type of radiation - You have already received radiation to the same area - Your overall health is too poor for radiation treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEFLASH RT

For T1 (small) lesions: 22 Gy single dose FLASH RT; For T2 (large) lesions: 5 x 6 Gy fractionated dose FLASH RT

DEVICEConventional RT

For T1 (small) lesions: 22 Gy single dose conventional RT; For T2 (large) lesions: 5 x 6 Gy fractionated dose conventional RT

Locations(1)

Centre Hospitalier Universitaire Vaudois (CHUV)

Lausanne, Canton of Vaud, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05724875

Related Trials

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

NCT035218301 location

Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma

NCT065673141 location

Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)

NCT053779051 location

Cutaneous Squamous Cell Carcinoma Staging Study

NCT056952222 locations

ctDNA in Cutaneous Squamous Cell Carcinoma

NCT068756091 location